ABOUT PROTO Axiom
Despite Australia’s strong biotech credentials, there is a distinct lack of early-stage venture capital funds to support and commercialise this science.
EXECUTIVE SUMMARY
Australia has world class science and favourable tax environments for biotech development.
A significant opportunity exists to translate globally competitive research from public investments into real-world outcomes.
Proto Axiom’s experienced team and strategic partners position our firm to unlock the potential of Australian biotech.
World-Class Science
Australia was ranked in the top five bio-economies globally in the 2018 Scientific American Worldwide Scoreboard.
Attractive R&D Tax Credits
R&D spending attracts a 43.5% cash rebate – Australia ranked by a 2016 KPMG report as
among the top ten most competitive locations
for R&D investment.
Globally Competitive Talent
and Research Base
In the 2020 edition of the QS World University
Rankings for Biological Sciences, Australia had
three universities ranked in the top 50 globally.
Favourable corporate tax regime
Recently announced corporate tax cuts for
profits derived from biotech patents
(“patent box”).